This guide compares the two forms, daily tablet versus weekly injection, and what that means in practice, while being clear that it does not compare their efficacy as UK fact, because the pill is not yet UK-licensed. It is grounded in the UK-licensed injection and is general information, not a claim about an unlicensed product.
The same molecule, two forms
The most important thing to understand is that the Wegovy pill and the Wegovy injection are the same active substance, semaglutide, delivered in two different ways 1. So they share the same underlying GLP-1 appetite-regulation mechanism: reducing energy intake and hunger 1.
The difference is the form, an oral tablet versus an injection, not the molecule 1. That is why the comparison is really about the practicalities of each form rather than two entirely different medicines 1.
It also means the biology this guide can rely on is the licensed injection's, which is the established reference for how semaglutide works 1. What the change of form means for the pill's own dose and effect in the UK would come from its licence once approved 3.
Daily tablet versus weekly injection
The clearest practical difference is frequency: the pill is expected to be a daily tablet, while the licensed injection is given weekly13. That is a meaningful difference in routine, a small daily action versus a single weekly one 1.
Neither is automatically better 1. A daily tablet means no needles, which appeals to many people, but it asks for a consistent daily routine; a weekly injection is a single action to remember but involves injecting 13. The right fit is personal 1.
For the underlying effect, the goal is the same, maintaining the GLP-1 appetite effect, but the rhythm of achieving it differs between a daily oral dose and a weekly injection 1. The pill would add a choice of form rather than replace the injection 13.
Administration: why the pill asks for more care
A key practical difference is that an oral semaglutide's administration is expected to matter more13. Peptides like semaglutide are not naturally well absorbed from the gut, so how a tablet is taken can affect how much gets in, in a way that does not apply to the injection 13.
The licensed injection's effectiveness does not depend on timing around food, which makes its administration relatively forgiving 1. An oral form is likely to need more careful, consistent administration to be absorbed reliably 3.
The pill's exact instructions would be set out in its UK product information once licensed, so this guide does not state them 3. The general point for the comparison is that the tablet would ask for a more exacting daily routine than the injection requires 13.
Want to know when the Wegovy pill (oral semaglutide) becomes available in the UK? It is not yet licensed here, but you can join the waitlist to be notified, and explore the licensed options with a Cloud Pharmacy clinician in the meantime.
Why we don't compare their effectiveness
An obvious question is which is more effective, but this guide does not compare their efficacy as UK fact 3. The injection has a UK results picture from its licence; the pill does not yet, because it is not UK-licensed, so a head-to-head efficacy claim would go beyond what UK sources support 13.
Comparing a licensed product's figures with an unlicensed product's trial data, possibly from different studies and populations, can mislead 13. The honest position is to wait for the pill's UK results picture before making such comparisons 3.
What can be said is that, as the same molecule, both are designed to work through the same appetite mechanism 1. Any difference in outcome between forms is exactly the kind of thing the pill's UK licence and assessment would clarify, rather than something to assume now 13.
Only the injection is available today
The decisive practical point is that, as of June 2026, only the injection is licensed and available in the UK; the pill is not yet UK-licensed13. So for anyone choosing now, the injection is the option that actually exists here 1.
That makes the comparison partly hypothetical for the moment: the pill would be a future alternative form, not a current choice 3. Weighing 'pill versus injection' as a real decision would only apply once the pill is licensed and available 13.
Until then, anyone interested in semaglutide for weight management would be considering the licensed injection, through a registered pharmacy or the NHS after assessment 12. Any 'Wegovy pill' offered now should be treated as a warning sign, given the NHS warning about fake weight-loss medicines 2.
How to choose, once both exist
If and when both forms are available, the choice would come down to personal fit within whatever each is licensed for: needle preference, the daily-versus-weekly routine, how the administration suits your life, and a clinician's view of what is appropriate for you 13. Effectiveness comparisons would draw on the pill's UK results picture once it exists 3.
For now, the practical advice is to consider the licensed injection with a prescriber if you want treatment, and to revisit the pill if and when it is licensed 12. Our guide on how to choose a weight-loss treatment sets the licensed options side by side 1.
The summary is simple: same molecule, two forms, daily tablet versus weekly injection, with only the injection available in the UK today 13. The pill would add a choice of form in future, decided with a prescriber on the basis of fit and its eventual UK licence 13.
What stays the same between the forms
It is worth being clear about what would not change between the two forms, because the shared molecule means a lot is held in common 1. Both are semaglutide acting on appetite regulation, both are meant to be used alongside a reduced-calorie diet and increased physical activity, and both belong to a class whose common side effects are gastrointestinal 1.
So the broad experience, an appetite effect that makes eating less more achievable, plus common gut symptoms that tend to be most noticeable early and to ease with time, would be a fair expectation for either form 1. The class behaviour is shared even where the form differs 1.
Both would also be prescription-only medicines requiring a proper assessment and obtained through a registered pharmacy, with the same emphasis on eligibility, suitability and follow-up 12. The route of administration changes; the seriousness of using the medicine responsibly does not 2.
Recognising this helps keep the comparison in proportion: the choice between pill and injection would be mostly about form and fit, set within a lot of shared ground, rather than a choice between two unrelated treatments 13.
Switching between forms
A question some people would have, once the pill exists, is whether they could switch between the injection and the tablet 13. As the same molecule in different forms, moving between them is conceivable, but it would be a clinical decision, not something to improvise 1.
Because the forms are dosed differently, a daily tablet versus a weekly injection, any switch would mean following the new form's own dosing rather than assuming an equivalent dose 13. The pill's UK dosing for this would be defined in its licence once approved 3.
So if switching is something you would consider in future, the right approach would be to discuss it with a prescriber, who could manage the change safely within each form's licence 12. It is not something to attempt by self-converting a dose or sourcing medicine independently 2.
For now this is hypothetical, since the pill is not yet UK-licensed, but it is a reasonable thing to keep in mind for the future, and a reminder that even 'same molecule' switches belong with a clinician rather than guesswork 13.
The wider point this comparison leaves you with is reassuring: whichever form you might eventually use, the medicine itself is the familiar semaglutide, and the differences are about how it is taken rather than what it is 1. That makes the eventual choice a practical one about fit, made with a prescriber, rather than a leap into something unknown 13. For now, though, that choice is hypothetical, and the licensed injection is the form actually available to consider with a prescriber today 13. Understanding the comparison in advance simply means you would be ready to make an informed choice if and when the pill is licensed here 13. There is no rush to decide on a form that is not yet available, and the licensed injection remains a well-established option in the meantime 12. Knowing how the two forms compare just means you can have a better-informed conversation with your prescriber when the time comes 13.
Frequently asked questions
Are the Wegovy pill and injection the same medicine?
They are the same active substance, semaglutide, in two forms: an oral tablet and a weekly injection 1. They share the same GLP-1 appetite-regulation mechanism 1.What's the main difference between them?
The form and routine: the pill is expected to be a daily tablet, the injection is weekly, and the tablet's administration is expected to matter more for absorption 13. Only the injection is licensed and available in the UK today 13.Which one works better?
This guide does not compare their efficacy as UK fact, because the pill is not yet UK-licensed and has no UK results picture 13. As the same molecule, both work through the same appetite mechanism; differences would be clarified by the pill's UK licence 1.Can I choose the pill instead of the injection now?
No. As of June 2026 only the injection is licensed and available in the UK; the pill is not yet UK-licensed 13. Any 'Wegovy pill' offered now is a warning sign, given the NHS warning about fake weight-loss medicines 2.Would the pill replace the injection?
No, it would add a choice of form rather than replace the injection 1. Neither is automatically better; the right fit depends on needle preference, routine and a clinician's view 13.How should I choose once both are available?
On personal fit within each form's licence: needle preference, daily-versus-weekly routine, administration, and a clinician's advice, with effectiveness drawn from the pill's UK results picture once it exists 13. For now, consider the licensed injection with a prescriber 12.Your next step
The Wegovy pill and the Wegovy injection are the same molecule, semaglutide, in two forms, so they share the same GLP-1 appetite-regulation mechanism. The useful differences are practical: the pill is expected to be a daily tablet versus the injection's weekly dose, and the tablet's administration is expected to matter more for absorption. This guide does not compare their efficacy as UK fact, because the pill is not yet UK-licensed and has no UK results picture.
The decisive point is that, as of June 2026, only the injection is licensed and available in the UK, so 'pill versus injection' is partly hypothetical until the pill is licensed. For now, anyone interested in semaglutide would be considering the licensed injection with a prescriber, through a registered pharmacy or the NHS, and any 'Wegovy pill' offered before licensing is a warning sign. If and when both forms exist, the choice would come down to personal fit and a clinician's view, informed by the pill's eventual UK licence.
Disclaimer
This guide is for general information only and does not constitute medical advice, diagnosis or treatment. The information here describes general clinical context based on UK regulatory sources cited above; it is not a recommendation for any specific medicine or treatment, which can only be made by a prescriber following individual assessment.
If you are considering treatment, speak to your GP or pharmacist, or arrange a consultation with a Cloud Pharmacy clinician. Prescription-only medicines are issued only after clinical assessment and where appropriate.
If you experience side effects from any medicine, you can report them through the Yellow Card scheme at yellowcard.mhra.gov.uk.
References
- Wegovy SmPC 4.1/4.2/5.1 (licensed INJECTION: semaglutide; weekly dosing; GLP-1 appetite-regulation mechanism; UK results picture exists for the injection; used to compare FORMS, not to assert the pill's efficacy)
- Semaglutide (registered pharmacy; some websites sell fake weight-loss medicines; assessment; general framing)
- General UK framing (June 2026); Wegovy pill not UK-licensed/available; only the injection available; daily-tablet vs weekly-injection and oral-absorption points framed as general/expected; pill efficacy/dose deferred to its UK licence
